Suven Pharmaceuticals, a technology-leading CDMO specializing in complex and innovate drug modalities, has announced the acquisition of 56% equity stake in “NJ Bio”.
The Company has acquired 56% equity stake in ‘NJ Bio’ at a USD 100 million pre-money valuation, investing USD 64.4 million, including USD 15 million for growth initiatives.
Suven Pharmaceuticals will acquire 56% stake in NJ Bio through a combination of primary and secondary:
- USD 49.4 mn for buying out the existing minority shareholders
- USD 15 mn as primary equity infusion
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape.
For more details visit- (https://nsearchives.nseindia.com/corporate/SUVENPHAR_07122024075909_Suvenpharm_pr_ip.pdf)
Also Read Paytm Singapore to sell its stock acquisition rights
